Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $175.28 USD
Change Today -0.96 / -0.54%
Volume 1.5M
ALXN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for alexion pharmaceuticals inc (ALXN)

Year over year, Alexion Pharmaceuticals, Inc. has been able to grow revenues from $1.6B USD to $2.2B USD. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold, SGA expenses and income tax expenses. All of these improvements led to a bottom line growth from $252.9M USD to $656.9M USD.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Reclassified
Dec 31
2012
Dec 31
2013
Restated
Dec 31
2014
4 Year
Trend
Revenues783.41,134.11,551.32,233.7
TOTAL REVENUES783.41,134.11,551.32,233.7
Cost of Goods Sold93.1126.2168.4173.9
GROSS PROFIT690.31,007.91,383.02,059.9
Selling General & Admin Expenses, Total308.2384.7489.7630.2
R&D Expenses137.4222.7317.1513.8
Depreciation & Amortization, Total0.40.40.4--
OTHER OPERATING EXPENSES, TOTAL446.0607.8807.21,144.0
OPERATING INCOME244.3400.1575.7915.9
Interest Expense-0.8-7.4-4.1-3.0
Interest and Investment Income1.91.83.38.4
NET INTEREST EXPENSE1.1-5.6-0.85.4
Currency Exchange Gains (Loss)-2.3-1.2-1.0-2.0
EBT, EXCLUDING UNUSUAL ITEMS243.2393.3574.0919.3
Merger & Restructuring Charges-13.5-22.8-5.0-35.7
Other Unusual Items, Total--27.1-42.7-11.5
In Process R&D Expenses---26.3-33.5-11.5
Other Unusual Items--53.4-9.2--
EBT, INCLUDING UNUSUAL ITEMS229.7397.6526.3872.1
Income Tax Expense54.4142.7273.4215.2
Earnings from Continuing Operations175.3254.8252.9656.9
NET INCOME175.3254.8252.9656.9
NET INCOME TO COMMON INCLUDING EXTRA ITEMS175.3254.8252.9656.9
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS175.3254.8252.9656.9
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $175.28 USD -0.96

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,856 GBp +5.00
Dr Reddy's Laboratories Ltd 4,096 INR -113.30
Sigma-Aldrich Corp $139.56 USD 0.00
Symrise AG €53.21 EUR +0.403
United Therapeutics Corp $149.96 USD -3.79
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 60.2x
Price/Sales 14.9x
Price/Book 4.7x
Price/Cash Flow 67.3x
TEV/Sales 14.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.